Silk Road Medical (NASDAQ:SILK) Announces Earnings Results, Beats Expectations By $0.04 EPS

Silk Road Medical (NASDAQ:SILK) issued its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.04, Briefing.com reports. Silk Road Medical had a negative return on equity of 36.38% and a negative net margin of 31.70%. The firm had revenue of $48.50 million for the quarter, compared to analyst estimates of $44.67 million. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. Silk Road Medical’s revenue for the quarter was up 20.9% on a year-over-year basis. Silk Road Medical updated its FY 2024 guidance to EPS.

Silk Road Medical Trading Down 5.5 %

Shares of SILK traded down $1.06 during midday trading on Wednesday, reaching $18.38. The company had a trading volume of 184,148 shares, compared to its average volume of 778,798. The firm has a 50 day simple moving average of $17.58 and a 200-day simple moving average of $13.44. The company has a quick ratio of 6.97, a current ratio of 7.95 and a debt-to-equity ratio of 0.50. Silk Road Medical has a 1-year low of $6.08 and a 1-year high of $44.11.

Insider Buying and Selling

In related news, EVP Kevin M. Klemz sold 2,497 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total transaction of $42,873.49. Following the completion of the sale, the executive vice president now directly owns 165,194 shares of the company’s stock, valued at approximately $2,836,380.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Silk Road Medical news, CAO Marie L. Jones sold 2,602 shares of Silk Road Medical stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total value of $44,676.34. Following the completion of the transaction, the chief accounting officer now directly owns 76,894 shares of the company’s stock, valued at approximately $1,320,269.98. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Kevin M. Klemz sold 2,497 shares of Silk Road Medical stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $17.17, for a total value of $42,873.49. Following the completion of the transaction, the executive vice president now directly owns 165,194 shares of the company’s stock, valued at $2,836,380.98. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,457 shares of company stock valued at $351,247. 6.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on SILK shares. JPMorgan Chase & Co. boosted their price target on Silk Road Medical from $10.00 to $19.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. Lake Street Capital started coverage on Silk Road Medical in a report on Wednesday, January 3rd. They issued a “buy” rating and a $20.00 price target for the company. Argus raised Silk Road Medical from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Thursday, March 7th. Stifel Nicolaus boosted their price target on Silk Road Medical from $20.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Finally, Piper Sandler boosted their price target on Silk Road Medical from $11.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $22.18.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.